Sun Pharmaceuticals Industries, Inc

Form 483 issued February 7, 2020 · Mohali, India

Inspection
Feb 3 – Feb 7, 2020
Observations
1
Pages
1
FEI number
3002807979

In short: On February 7, 2020, FDA issued a Form 483 with 1 observation to Sun Pharmaceuticals Industries, Inc in Mohali, Punjab (FEI 3002807979) after an inspection that ran Feb 3 – Feb 7, 2020. The investigators were Jeffrey P. Raimondi and Philip F. Istafanos. Most observations concern laboratory controls; the most-cited regulation is 21 CFR 211.165 (testing and release for distribution).

At a glance

1 of 1 observations on this 483 concern laboratory controls.

Laboratory controls1

Most cited: 21 CFR 211.165 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Each batch of drug product required to be free of objectionable microorganisms is not tested…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Sun Pharmaceuticals Industries, Inc?

FDA listed 1 observation on this Form 483, mostly about laboratory controls. The most-cited regulation is 21 CFR 211.165 (testing and release for distribution). The opening words of each observation are shown on this page.

Who inspected Sun Pharmaceuticals Industries, Inc?

Jeffrey P. Raimondi and Philip F. Istafanos are named on this Form 483, for the inspection of Feb 3 – Feb 7, 2020. Each investigator has a profile showing what they cite most.

When was Sun Pharmaceuticals Industries, Inc inspected by FDA?

The inspection ran Feb 3 – Feb 7, 2020, and the Form 483 is dated February 7, 2020.

How do I get the full Form 483 for Sun Pharmaceuticals Industries, Inc?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free